Salarius Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Nov 7, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Dec 31, 2024 · Filed Nov 7, 2025
Contents
Pay Versus Performance Table
| Year | Summary CompensationTable for PEO(1) | Compensation Actually Paid to PEO(2)(3) | AverageSummary Compensation Table Totals for non-PEO NEOs(1) | AverageCompensation ActuallyPaid to non-PEO NEO(2)(3) | Value of Initial Fixed $100 InvestmentBased On: Total Shareholder Return | Net Loss (in millions) |
|---|---|---|---|---|---|---|
| 2024 | $734,450 | $727,586 | $350,422 | $343,233 | $1.86 | $5.58 |
| 2023 | $544,600 | $516,927 | $355,760 | $345,284 | $5.25 | $12.54 |
| 2022 | $941,023 | $609,104 | $494,554 | $383,431 | $12.35 | $31.61 |
(1)The PEO for 2024, 2023 and 2022 is David Arthur. The Non-PEO NEO for whom the average compensation is presented in the table for 2024, 2023 and 2022 is Mark Rosenblum.
(2)The amounts shown as Compensation Actually Paid (“CAP”) have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually realized or received by the Company’s PEO and Non-PEO NEO. These amounts reflect total compensation as set forth in the Summary Compensation Table for each year, adjusted as described in footnote 3 below.
(3)CAP reflects the exclusions and inclusions for the PEO and the Non-PEO NEO set forth below. Amounts excluded, which are set forth in the “Minus Stock and Option Awards from Summ. Comp. Table” columns below, represent the stock awards and option awards reported in the Stock Awards and Option Awards columns of the Summary Compensation Table for each applicable year. Amounts added back to determine CAP are made up of the following components which are set forth in the table below, as applicable: (i) the fair value as of the end of the fiscal year of outstanding and unvested equity awards granted in that year; (ii) the change in fair value during the year of equity awards granted in prior years that remained outstanding and unvested at the end of the year; (iii) the fair value as of the vesting date of equity awards that were granted and vested in that year; and (iv) the change in fair value during the year through the vesting date of equity awards granted in prior years that vested during that year. The fair value at the end of the prior year of awards granted in any prior year that failed to meet applicable vesting conditions during the covered year are subtracted. Equity values are calculated in accordance with ASC Topic 718.
| Year | Summary Comp. Table Total for PEO | Minus Stock and Option Awards from Summ. Comp. Table | Plus Year-End Equity Value of Unvested Awards Granted During Year | Plus Changein Value of Unvested AwardsGranted in Prior Years | Plus Value of Awards Granted and Vested During Year | Plus Change in Value of Prior Years’ Awards Vested During Year | Comp. Actually Paid to PEO |
|---|---|---|---|---|---|---|---|
| 2024 | $734,450 | $8,265 | $1,522 | ($163) | $0 | $42 | $727,586 |
| 2023 | $544,600 | $31,400 | $13,000 | ($10,395) | $0 | $1,122 | $516,927 |
| 2022 | $941,023 | $211,448 | $20,526 | ($101,823) | $0 | ($39,174) | $609,104 |
| Year | Summary Comp. Table Total for Other NEO | MinusStock and Option Awards from Summ. Comp. Table | PlusYear-End Equity Value of Unvested Awards Granted During Year | Plus Change in Value of Unvested Awards Granted in Prior Years | Plus Value of AwardsGranted and Vested During Year | Plus Change in Value of Prior Years’ Awards Vested During Year | Comp. Actually Paid to Other NEO |
|---|---|---|---|---|---|---|---|
| 2024 | $350,422 | $11,372 | $4,230 | $(65) | $0 | $18 | $343,233 |
| 2023 | $355,760 | $12,560 | $5,200 | $(3,791) | $0 | $675 | $345,284 |
| 2022 | $494,554 | $84,579 | $8,210 | $(24,959) | $0 | $(9,795) | $383,431 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.